Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444556 · ClinicalTrials.gov registry record · Phase 1
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 3
- Study locations
NCT05444556: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.
NCT05444556 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 113 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05444556, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.
Primary Outcome
PK: AUC\[0-∞\] of Repaglinide
Conditions Studied
Interventions
- DRUG Omeprazole
- DRUG Dextromethorphan
- DRUG Imlunestrant
- DRUG Repaglinide
- DRUG Quinidine
Study Locations (3)
California
- Altasciences Clinical Los Angeles, Inc - Cypress
Florida
- Qps-Mra, Llc - South Miami
Texas
- ICON Early Phase Services - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2022-11-02 |
| Phase | Phase 1 |
What the finished NCT05444556 record still lists
NCT05444556 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which Omeprazole is the first listed.
NCT05444556 reports a single indexed study location in California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05444556 about?
NCT05444556 is a clinical study titled "A Study of Imlunestrant (LY3484356) in Female Healthy Participants". The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and...
What is the current status of trial NCT05444556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2022-07-07. Estimated completion is 2022-11-02.
What conditions does trial NCT05444556 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05444556?
The interventions under investigation include: Omeprazole (DRUG), Dextromethorphan (DRUG), Imlunestrant (DRUG), Repaglinide (DRUG), Quinidine (DRUG).
Who is sponsoring clinical trial NCT05444556?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05444556 being conducted?
This trial has 3 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05444556's enrollment target sits among peer trials
113 202nd of 1090 higher than 889 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI